Development of novel osteoporosis medication which focusses on the renin angiotensin system in osteocytes
Project/Area Number |
25462360
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Orthopaedic surgery
|
Research Institution | Tokyo Medical and Dental University |
Principal Investigator |
Morita Sadao 東京医科歯科大学, 医学部附属病院, 准教授 (20202426)
|
Co-Investigator(Kenkyū-buntansha) |
ASOU Yoshinori 東京医科歯科大学, 大学院医歯学総合研究科, 准教授 (50345279)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 骨細胞 / レニン・アンジオテンシン系 |
Outline of Final Research Achievements |
In this study, we evaluated the role of renin angiotensin system in osteocytes by using osteocyte-specific RAS related gene-deficient mice. These conditional knockout mice showed that cortical bone mass is significantly increased. In contrast, trabecular bone mass was not changed. The expression of the osteoblast differentiation markers in the cortical bone in cKO mice is significantly increased. When the primary osteoblasts were co-cultured with RAS related gene knocked-down osteocytes, the osteoblasts activity was significantly increased. These results suggest that RAS related gene in osteocytes regulate indirectly the osteoblast activity and maintain the bone metabolism.
|
Report
(3 results)
Research Products
(7 results)